In Situ Forming Injectable Hydrogel For Encapsulation Of Nanoiguratimod And Sustained Release Of Therapeutics

References

• Mahajan TD, Mikuls TR. Recent advances in the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2018;30(3):231–237.doi:10.1097/BOR.000000000000049629461286
   PubMedGoogle Scholar
• Komatsu N, Takayanagi H. [Bone and cartilage destruction in rheumatoid arthritis]. Clin Calcium. 2012;22(2):179–185. doi :CliCa120217918522298070
   PubMedGoogle Scholar
• Corbacho MI, Dapueto JJ. Assessing the functional status and quality of life of patients with rheumatoid arthritis. Rev Bras Reumatol. 2010;50(1):31–43. doi:10.1590/S0482-5004201000010000421125139
   PubMedGoogle Scholar
• Goekoop-Ruiterman YP, Huizinga TW. Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA? Nat Rev Rheumatol. 2010;6(2):68–70. doi:10.1038/nrrheum.2009.25320125170
   PubMedGoogle Scholar
• Osiri M, Deesomchok U, Tugwell P. Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice. Clin Rheumatol. 2006;25(5):721–727. doi:10.1007/s10067-005-0155-416365685
   PubMedGoogle Scholar
• Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11 Suppl 1: S1.doi:10.1186/ar266619368701
   PubMed Web of Science ®Google Scholar
• Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet. 2002;359(9306):540–541. doi:10.1016/S0140-6736(02)07718-811867103
   PubMedGoogle Scholar
• Chou CT. The high cost of anti-TNFalpha drugs for rheumatoid arthritis: can a low-price product be developed in the future? J Chin Med Assoc. 2012;75(2):51–53. doi:10.1016/j.jcma.2011.12.01222340736
   PubMedGoogle Scholar
• Mello SB, Tavares ER, Bulgarelli A, Bonfa E, Maranhao RC. Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis. Int J Nanomedicine. 2013;8:443–449. doi:10.2147/IJN.S2939223439784
   PubMed Web of Science ®Google Scholar
• Prabhu P, Shetty R, Koland M, et al. Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity. Int J Nanomedicine. 2012;7:177–186. doi:10.2147/IJN.S2531022275833
   PubMed Web of Science ®Google Scholar
• Mucke HA. Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today (Barc). 2012;48(9):577–586. doi:10.1358/dot.2012.48.9.185575823032798
   PubMed Web of Science ®Google Scholar
• Li J, Mao H, Liang Y, et al. Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis. Clin Dev Immunol. 2013;2013:310628. doi:10.1155/2013/31062824371446
   PubMedGoogle Scholar
• Jinno J, Kamada N, Miyake M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006; 111 (1–2): 56–64. doi:10.1016/j.jconrel.2005.11.01316410029
   PubMed Web of Science ®Google Scholar
• Tokatlian T, Cam C, Siegman SN, Lei Y, Segura T. Design and characterization of microporous hyaluronic acid hydrogels for in vitro gene transfer to mMSCs. Acta Biomater. 2012;8(11):3921–3931. doi:10.1016/j.actbio.2012.07.014
   Google Scholar
• Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2012;51 Suppl 6: vi5–vi9. doi:10.1093/rheumatology/kes27923221588
   PubMedGoogle Scholar
• Zimmermann T, Kunisch E, Pfeiffer R, et al. Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture–primary culture cells markedly differ from fourth-passage cells. Arthritis Res. 2001;3(1):72–76. doi:10.1186/ar14211178129
   PubMedGoogle Scholar
• Zhou T, Ding L, Li X, et al. Determination of iguratimod in rat plasma by high performance liquid chromatography: method and application. Biomed Chromatogr. 2008;22(3):260–264. doi:10.1002/bmc.92117939167
   PubMedGoogle Scholar
• Hirose J, Tanaka S. [Animal models for bone and joint disease. CIA, CAIA model]. Clin Calcium. 2011;21(2):253–259. CliCa110225325921289422
   PubMedGoogle Scholar
• Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature. 1980;283(5748):666–668. doi:10.1038/283666a06153460
   PubMed Web of Science ®Google Scholar
• Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol. 2006;41(5):798–806. doi:10.1016/j.yjmcc.2006.07.00416919293
   PubMedGoogle Scholar
• Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl. 1993;39:3–9.8410881
   PubMedGoogle Scholar
• Balazs EA. Viscosupplementation for treatment of osteoarthritis: from initial discovery to current status and results. Surg Technol Int. 2004;12:278–289.15455338
   PubMedGoogle Scholar
• Hahn SK, Kim SJ, Kim MJ, Kim DH. Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. Pharm Res. 2004;21(8):1374–1381. doi:10.1023/b:pham.0000036910.41224.de15359571
   PubMed Web of Science ®Google Scholar
• Kim SJ, Hahn SK, Kim MJ, Kim DH, Lee YP. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J Control Release. 2005;104(2):323–335. doi:10.1016/j.jconrel.2005.02.01215907583
   PubMed Web of Science ®Google Scholar
• Ohri R, Hahn SK, Hoffman AS, Stayton PS, Giachelli CM. Hyaluronic acid grafting mitigates calcification of glutaraldehyde-fixed bovine pericardium. J Biomed Mater Res A. 2004;70(2):328–334. doi:10.1002/jbm.a.3008815227678
   PubMedGoogle Scholar
• Kuroki H, Nakagawa Y, Mori K, et al. Acoustic stiffness and change in plug cartilage over time after autologous osteochondral grafting: correlation between ultrasound signal intensity and histological score in a rabbit model. Arthritis Res Ther. 2004;6(6):R492–504. doi:10.1186/ar121915535827
   PubMedGoogle Scholar
• Krenn V, Morawietz L, Burmester GR, et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology. 2006;49(4):358–364. doi:10.1111/j.1365-2559.2006.02508.x16978198
   PubMed Web of Science ®Google Scholar
• Horn D, Rieger J. Organic nanoparticles in the aqueous phase-theory, experiment, and use. Angew Chem Int Ed Engl. 2001;40(23):4330–4361. doi:10.1002/1521-3773(20011203)40:23<4330::AID-ANIE4330>3.0.CO;2-W12404417
   PubMed Web of Science ®Google Scholar
• Silber BM, Rao S, Fife KL, et al. Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice. Pharm Res. 2013;30(4):932–950. doi:10.1007/s11095-012-0912-423417511
   PubMedGoogle Scholar
• Rausch-Derra LC, Rhodes L, Freshwater L, Hawks R. Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs. J Vet Pharmacol Ther. 2016;39(6):566–571. doi:10.1111/jvp.1230627027634
   PubMedGoogle Scholar
• Portoles A, Almeida S, Terleira A, et al. Truncated AUC in the evaluation of fluconazole bioequivalence. A cross-over, randomised, open-label study in healthy volunteers. Arzneimittelforschung. 2004;54(11):752–756. doi:10.1055/s-0031-129703215612616
   PubMedGoogle Scholar
• Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX, Jiang YF. Plasma levels of IL-37 and correlation with TNF-alpha, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS One. 2014;9(5):e95346. doi:10.1371/journal.pone.009534624788826
   PubMedGoogle Scholar
• Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31(6):784–788. doi:10.1002/art.17803106143260102
   PubMedGoogle Scholar
• Lettesjo H, Nordstrom E, Strom H, et al. Synovial fluid cytokines in patients with rheumatoid arthritis or other arthritic lesions. Scand J Immunol. 1998;48(3):286–292. doi:10.1046/j.1365-3083.1998.00399.x9743215
   PubMedGoogle Scholar
• Lee F, Chung JE, Kurisawa M. An injectable hyaluronic acid-tyramine hydrogel system for protein delivery. J Control Release. 2009;134(3):186–193. doi:10.1016/j.jconrel.2008.11.02819121348
   PubMed Web of Science ®Google Scholar
• Nakaji-Hirabayashi T, Kato K, Iwata H. Hyaluronic acid hydrogel loaded with genetically-engineered brain-derived neurotrophic factor as a neural cell carrier. Biomaterials. 2009;30(27):4581–4589. doi:10.1016/j.biomaterials.2009.05.00919501903
   PubMedGoogle Scholar
• Lei Y, Huang S, Sharif-Kashani P, Chen Y, Kavehpour P, Segura T. Incorporation of active DNA/cationic polymer polyplexes into hydrogel scaffolds. Biomaterials. 2010;31(34):9106–9116. doi:10.1016/j.biomaterials.2010.08.01620822811
   PubMedGoogle Scholar
• Liu J, Qi C, Tao K, et al. Sericin/dextran injectable hydrogel as an optically trackable drug delivery system for malignant melanoma treatment. ACS Appl Mater Interfaces. 2016;8(10):6411–6422. doi:10.1021/acsami.6b0095926900631
   PubMed Web of Science ®Google Scholar
• Liu M, Song X, Wen Y, Zhu JL, Li J. Injectable thermoresponsive hydrogel formed by alginate-g-poly(N-isopropylacrylamide) that releases doxorubicin-encapsulated micelles as a smart drug delivery system. ACS Appl Mater Interfaces. 2017;9(41):35673–35682. doi:10.1021/acsami.7b1284928937214
   PubMed Web of Science ®Google Scholar
• Thambi T, Li Y, Lee DS. Injectable hydrogels for sustained release of therapeutic agents. J Control Release. 2017;267:57–66. doi:10.1016/j.jconrel.2017.08.00628827094
   PubMed Web of Science ®Google Scholar
• Kang L, Gao Z, Huang W, Jin M, Wang Q. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharm Sin B. 2015;5(3):169–175. doi:10.1016/j.apsb.2015.03.00126579443
   PubMed Web of Science ®Google Scholar
• Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3(9):785–796. doi:10.1038/nrd149415340388
   PubMed Web of Science ®Google Scholar
• Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3–19. doi:10.1016/S0169-409X(00)00118-611251242
   PubMed Web of Science ®Google Scholar
• Hu J, Johnston KP, Williams RO, 3rd. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm. 2004;30(3):233–245. doi:10.1081/DDC-12003042215109023
   PubMed Web of Science ®Google Scholar
• Cushing BL, Kolesnichenko VL, O’Connor CJ. Recent advances in the liquid-phase syntheses of inorganic nanoparticles. Chem Rev. 2004;104(9):3893–3946. doi:10.1021/cr030027b15352782
   PubMed Web of Science ®Google Scholar
• Elbert DL, Pratt AB, Lutolf MP, Halstenberg S, Hubbell JA. Protein delivery from materials formed by self-selective conjugate addition reactions. J Control Release. 2001; 76 (1–2): 11–25. doi:10.1016/S0168-3659(01)00398-411532309
   PubMedGoogle Scholar
• Shu XZ, Ahmad S, Liu Y, Prestwich GD. Synthesis and evaluation of injectable, in situ crosslinkable synthetic extracellular matrices for tissue engineering. J Biomed Mater Res A. 2006;79(4):902–912. doi:10.1002/jbm.a.3083116941590
   PubMed Web of Science ®Google Scholar
• Lei Y, Gojgini S, Lam J, Segura T. The spreading, migration and proliferation of mouse mesenchymal stem cells cultured inside hyaluronic acid hydrogels. Biomaterials. 2011;32(1):39–47. doi:10.1016/j.biomaterials.2010.08.10320933268
   PubMed Web of Science ®Google Scholar
• Tanaka K, Yamamoto T, Aikawa Y, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford). 2003;42(11):1365–1371. doi:10.1093/rheumatology/keg38112810927
   PubMed Web of Science ®Google Scholar